sh-Polypeptide-59 for Hair Regrowth

Created on 11/08/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Opus 5.5 – Audit

sh-Polypeptide-59, a lab-made copy of a natural repair protein released by blood platelets, is a cosmetic ingredient in scalp serums sold for fuller hair. In mice it switches resting hair follicles into growth, but no study has tested it on human hair, and so large a protein may not cross unbroken scalp skin. A plausible but untested add-on; scalp skin cancer or known cancer elsewhere is the clearest concern. (Full Review)

Protocol

Drug reference dose
Becaplermin gel 100 µg/g
Up to 20 weeks on ulcers; no established hair dose, and the reviewed serum does not disclose its active concentrations
Single or split dosing
Once daily, single application
Mirrors the becaplermin schedule; no data support splitting or favor a time of day
Pre-existing conditions
Add-on to established hair-loss drugs
In pattern hair loss, PDGF (platelet-derived growth factor) leaves the hormone pathway driving it (DHT) untouched; practitioners pair growth-factor products with established drugs rather than replacing them
Time to effect
Post-procedure facial skin
30 days
Better blinded aesthetic ratings than an emollient after microneedling; a single small trial
Hair density
3–6 months
Gains seen with platelet injections, not the ingredient; judging before 6 months is premature
Ulcer closure
Within 20 weeks
Becaplermin gel on open diabetic ulcers; not hair

Benefits

Contraindications
  • Known skin cancer or other neoplasm on the scalp area to be treated
  • Known cancer elsewhere (careful benefit-risk evaluation)
  • Pregnancy or breastfeeding (inferred; no human data)
  • Scarring alopecia (inferred; no human data on added PDGF)
  • Sensitization to product preservatives
Key Interactions
Theoretical (inferred from mechanism)
  • Microneedling (procedure): persistent nodules
  • PDGF receptor tyrosine kinase inhibitors (imatinib, sunitinib): any hair effect would be expected to disappear
  • Topical minoxidil (OTC, over-the-counter): more vehicle irritation from layered products
  • Topical retinoids (vitamin A–derived skin drugs: tretinoin) and salicylic acid: more irritation and dermal exposure
  • Topical corticosteroids (anti-inflammatory steroid creams: OTC hydrocortisone): a possible blunted effect
  • Finasteride and dutasteride: none expected beyond each drug's own effects
  • Copper tripeptide-1 (GHK-Cu) and other synthetic growth-factor peptides (sh-Oligopeptide-1): unknown cumulative proliferative stimulation
  • Oral hair supplements (biotin, iron): none expected
  • PRP injections: additive local PDGF exposure of unknown effect

Risk & Side Effects

  • High:
  • Medium:
  • Low: Application-Site Irritation and Sensitization; Cancer Distant from the Application Site; Granulomas When Delivered by Microneedling
  • Speculative: Fibrotic Signaling in Scarring Hair Loss; Local Proliferative Overstimulation

Monitoring

Marker Target Why
Hair density (hairs/cm²) No established target; track change from own baseline at the marked site Expected to change if the product works
Anagen hair percentage No established target; track change from own baseline Growth-phase share should rise
Mean hair shaft diameter No established target; track change from own baseline Thicker shafts indicate follicle recovery
Scalp skin examination No established target; any new, changing or bleeding lesion Safety check: a lesion stops use at that site

Cadence: Baseline scalp photographs, marked-site hair count and scalp skin examination; repeated at 3 and 6 months, then every 6–12 months, with yearly dermatologist review; no blood tests needed. Success: measurable gain in density or shaft diameter versus own baseline at 6 months

Qualitative Assessment

  • Daily shedding volume (hairs on pillow, in the drain or brush)
  • Visible scalp show-through on standardized photographs
  • Hair volume and ease of styling
  • Scalp comfort: itching, burning, redness or flaking after application